AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts remain broadly positive: AtriCure has a “Moderate Buy” consensus from 11 analysts, with an average 12-month price target of $48.50 versus a recent share price of $39.49.
• Quarterly results exceeded expectations: The medical-device company reported $0.18 in quarterly EPS and $153.6 million in revenue, topping the $151.8 million analyst estimate. Fiscal 2026 EPS guidance is $0.24–$0.32.
• Ownership and trading activity were mixed: Institutional investors own 99.11% of the stock, while insiders sold 40,182 shares worth approximately $1.5 million over the past 90 days. AtriCure shares have risen above their 50-day and 200-day moving averages but trade at a high price-to-earnings ratio of 188.06.

Shares of AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $48.50.

ATRC has been the topic of several research analyst reports. Zacks Research upgraded shares of AtriCure from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 24th. UBS Group reduced their target price on AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, July 28th. Canaccord Genuity Group raised their target price on AtriCure from $53.00 to $55.00 and gave the stock a "buy" rating in a research report on Wednesday, May 6th. Weiss Ratings upgraded AtriCure from a "sell (e+)" rating to a "sell (d+)" rating in a report on Tuesday, July 28th. Finally, Citigroup reissued a "market outperform" rating on shares of AtriCure in a research report on Tuesday, July 21st.

Insider Activity at AtriCure

In other news, insider Vinayak Doraiswamy sold 6,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the sale, the insider directly owned 86,511 shares of the company's stock, valued at $3,363,547.68. This represents a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Sven Wehrwein sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the transaction, the director directly owned 40,518 shares in the company, valued at $1,533,201.12. The trade was a 38.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 40,182 shares of company stock valued at $1,505,092 over the last ninety days. 4.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On AtriCure

Several institutional investors and hedge funds have recently modified their holdings of the stock. Global Retirement Partners LLC purchased a new stake in shares of AtriCure during the second quarter worth $52,000. Bank of New York Mellon Corp acquired a new stake in AtriCure during the second quarter valued at $3,953,000. Handelsbanken Fonder AB grew its stake in AtriCure by 12.3% in the second quarter. Handelsbanken Fonder AB now owns 22,800 shares of the medical device company's stock valued at $638,000 after purchasing an additional 2,500 shares in the last quarter. Tactive Advisors LLC purchased a new position in AtriCure in the second quarter valued at about $374,000. Finally, Assenagon Asset Management S.A. acquired a new position in AtriCure in the 2nd quarter worth about $1,744,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Stock Performance

Shares of ATRC opened at $39.49 on Friday. The company has a 50-day moving average of $31.98 and a two-hundred day moving average of $31.31. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of 188.06 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure has a one year low of $25.36 and a one year high of $43.18.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter in the previous year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts expect that AtriCure will post 0.2 earnings per share for the current year.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source